BRD7 and neoplasm: It is pointed out in the literature that BRD7-deficient tumor cells exhibit increased sensitivity to interferon- γ, promote the activation of effector T cells and kill tumor cells [11], suggesting that BRD7 may be a very promising target for tumor immunotherapy.